Alessandro M. Carabelli

Alessandro M. Carabelli

Auto-generated profile, based on publicly available information

Alessandro M. Carabelli

Department of Medicine, University of Cambridge, Addenbrookes Hospital, Cambridge, UK

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
WHWilliam T. Harvey
William T. Harvey
ACAlessandro M. Carabelli
Alessandro M. Carabelli
BJBen Jackson
Ben Jackson
RGRavindra K. Gupta
Ravindra K. Gupta
ETEmma C. Thomson
Emma C. Thomson
DRDavid L. Robertson
David L. Robertson

18 January 2023 in Nature Reviews Microbiology
Verified
Journal Article
Open access
PDF file
ACAlessandro M. Carabelli
Alessandro M. Carabelli
TPThomas P. Peacock
Thomas P. Peacock
LTLucy G. Thorne
Lucy G. Thorne
WHWilliam T. Harvey
William T. Harvey
JHJoseph Hughes
Joseph Hughes
DRDavid L. Robertson
David L. Robertson
In late 2020, after circulating for almost a year in the human population, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibited a major step change in its adaptation to humans. These highly mutated forms of SARS-CoV-2 had enhanced rates of transmission relative to previous variants and were termed ‘variants of concern’ (VOCs). Designated Alpha, Beta, Gamma, Delta and Omicron, the VOCs emerged independently from one another, and in turn each rapidly became dominant, regionally or globally, outcompeting previous variants. The success of each VOC relative to the previously dominant variant was enabled by altered intrinsic functional properties of the virus and, to various degrees, changes to virus antigenicity conferring the ability to evade a primed immune response. The increased virus fitness associated with VOCs is the result of a complex interplay of virus biology in the context of changing human immunity due to both vaccination and prior infection. In this Review, we summarize the literature on the relative transmissibility and antigenicity of SARS-CoV-2 variants, the role of mutations at the furin spike cleavage site and of non-spike proteins, the potential importance of recombination to virus success, and SARS-CoV-2 evolution in the context of T cells, innate immunity and population immunity. SARS-CoV-2 shows a complicated relationship among virus antigenicity, transmission and virulence, which has unpredictable implications for the future trajectory and disease burden of COVID-19.

28 October 2022 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
MCMacGregor Cox
MacGregor Cox
TPThomas P. Peacock
Thomas P. Peacock
WHWilliam T. Harvey
William T. Harvey
JHJoseph Hughes
Joseph Hughes
DWDerek W. Wright
Derek W. Wright
ACAlessandro M. Carabelli
Alessandro M. Carabelli

26 August 2022 in Virus Evolution
Verified
Journal Article
Open access
PDF file
VHVerity Hill
Verity Hill
LPLouis Du Plessis
Louis Du Plessis
TPThomas P Peacock
Thomas P Peacock
DADinesh Aggarwal
Dinesh Aggarwal
RCRachel Colquhoun
Rachel Colquhoun
ARAndrew Rambaut
Andrew Rambaut
The first SARS-CoV-2 variant of concern (VOC) to be designated was lineage B.1.1.7, later labelled by the World Health Organization as Alpha. Originating in early autumn but discovered in December 2020, it spread rapidly and caused large waves of infections worldwide. The Alpha variant is notable for being defined by a long ancestral phylogenetic branch with an increased evolutionary rate, along which only two sequences have been sampled. Alpha genomes comprise a well-supported monophyletic clade within which the evolutionary rate is typical of SARS-CoV-2. The Alpha epidemic continued to grow despite the continued restrictions on social mixing across the UK and the imposition of new restrictions, in particular, the English national lockdown in November 2020. While these interventions succeeded in reducing the absolute number of cases, the impact of these non-pharmaceutical interventions was predominantly to drive the decline of the SARS-CoV-2 lineages that preceded Alpha. We investigate the only two sampled sequences that fall on the branch ancestral to Alpha. We find that one is likely to be a true intermediate sequence, providing information about the order of mutational events that led to Alpha. We explore alternate hypotheses that can explain how Alpha acquired a large number of mutations yet remained largely unobserved in a region of high genomic surveillance: an under-sampled geographical location, a non-human animal population, or a chronically infected individual. We conclude that the latter provides the best explanation of the observed behaviour and dynamics of the variant, although the individual need not be immunocompromised, as persistently infected immunocompetent hosts also display a higher within-host rate of evolution. Finally, we compare the ancestral branches and mutation profiles of other VOCs and find that Delta appears to be an outlier both in terms of the genomic locations of its defining mutations and a lack of the rapid evolutionary rate on its ancestral branch. As new variants, such as Omicron, continue to evolve (potentially through similar mechanisms), it remains important to investigate the origins of other variants to identify ways to potentially disrupt their evolution and emergence.

18 March 2022 in Virus Evolution
Verified
Journal Article
Open access
PDF file
DWDerek W Wright
Derek W Wright
WHWilliam T Harvey
William T Harvey
JHJoseph Hughes
Joseph Hughes
MCMacGregor Cox
MacGregor Cox
TPThomas Peacock
Thomas Peacock
ACAlessandro M Carabelli
Alessandro M Carabelli
COG-UK Mutation Explorer (COG-UK-ME, https://sars2.cvr.gla.ac.uk/cog-uk/ - Last Accessed date 16/03/22) is a web resource that displays knowledge and analyses on SARS-CoV-2 virus genome mutations and variants circulating in the UK, with a focus on the observed amino acid replacements that have an antigenic role in the context of the human humoral and cellular immune response. This analysis is based on more than 2 million genome sequences (as of March 2022) for UK SARS-CoV-2 data held in the CLIMB-COVID centralised data environment. COG-UK-ME curates these data and displays analyses that are cross-referenced to experimental data collated from the primary literature. The aim is to track mutations of immunological importance that are accumulating in current variants of concern and variants of interest that could alter the neutralising activity of monoclonal antibodies (mAbs), convalescent sera and vaccines. Changes in epitopes recognised by T cells, including those where reduced T cell binding has been demonstrated, are reported. Mutations that have been shown to confer SARS-CoV-2 resistance to antiviral drugs are also included. Using visualisation tools, COG-UK-ME also allows users to identify the emergence of variants carrying mutations that could decrease the neutralising activity of both mAbs present in therapeutic cocktails, e.g., Ronapreve. COG-UK-ME tracks changes in frequency of combination of mutations and brings together curated literature on the impact of those mutations on various functional aspects of the virus and therapeutics. Given SARS-CoV-2 unpredictable nature as exemplified by yet another variant of concern, Omicron, continued surveillance of SARS-CoV-2 remains imperative to monitor virus evolution linked to the efficacy of therapeutics.

27 January 2023 in Science Advances
Verified
Journal Article
Open access
JDJEAN-FREDERIC DUBERN
JEAN-FREDERIC DUBERN
AHAndrew Hook
Andrew Hook
ACAlessandro M. Carabelli
Alessandro M. Carabelli
CCChien-Yi Chang
Chien-Yi Chang
CLChristopher A. Lewis-Lloyd
Christopher A. Lewis-Lloyd
PWPaul Williams
Paul Williams
Innovative approaches to prevent catheter-associated urinary tract infections (CAUTIs) are urgently required. Here, we describe the discovery of an acrylate copolymer capable of resisting single- and multispecies bacterial biofilm formation, swarming, encrustation, and host protein deposition, which are major challenges associated with preventing CAUTIs. After screening ~400 acrylate polymers, poly( tert -butyl cyclohexyl acrylate) was selected for its biofilm- and encrustation-resistant properties. When combined with the swarming inhibitory poly(2-hydroxy-3-phenoxypropyl acrylate), the copolymer retained the bioinstructive properties of the respective homopolymers when challenged with Proteus mirabilis , Pseudomonas aeruginosa , Staphylococcus aureus , and Escherichia coli . Urinary tract catheterization causes the release of host proteins that are exploited by pathogens to colonize catheters. After preconditioning the copolymer with urine collected from patients before and after catheterization, reduced host fibrinogen deposition was observed, and resistance to diverse uropathogens was maintained. These data highlight the potential of the copolymer as a urinary catheter coating for preventing CAUTIs.